Mylan settles cancer drug patent dispute with Genentech

15-03-2017

Mylan settles cancer drug patent dispute with Genentech

mediaphotos / iStockphoto.com

Mylan has entered a settlement with Genentech and its parent company, Roche, in relation to patents for cancer drug Herceptin (trastuzumab).


Mylan, IPR, Genentech, settlement, Roche, patent, Herceptin, patent infringement, inter partes review, cancer drug, biosimilar

LSIPR